

# Eduardo Collantes Estévez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6055322/publications.pdf>

Version: 2024-02-01

245  
papers

11,314  
citations

53794

45  
h-index

30922

102  
g-index

260  
all docs

260  
docs citations

260  
times ranked

8378  
citing authors

#	ARTICLE	IF	CITATIONS
1	Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 56-67.	0.9	18
2	Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 662.	2.4	3
3	Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO. <i>Arthritis Research and Therapy</i> , 2022, 24, 30.	3.5	6
4	Impact of the number of comorbidities on the outcome measures and on the retention rate of the first anti-TNF in patients with Ankylosing Spondylitis. Two-year follow-up in REGISPONSER-AS. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151938.	3.4	1
5	Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. <i>Reumatología Clínica (English Edition)</i> , 2022, 18, 169-176.	0.3	0
6	The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. <i>Journal of Internal Medicine</i> , 2022, 291, 676-693.	6.0	11
7	Understanding the Disease Burden of Unemployed Patients With Axial Spondyloarthritis: Results From the Spanish Atlas 2017. <i>Journal of Rheumatology</i> , 2022, 49, 373-379.	2.0	2
8	Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2022, 12, 64.	2.6	1
9	COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e50-e50.	0.9	32
10	Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. <i>Rheumatology</i> , 2021, 60, 113-124.	1.9	3
11	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
12	Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. <i>Joint Bone Spine</i> , 2021, 88, 105085.	1.6	23
13	Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONSER registry. <i>Rheumatology</i> , 2021, 60, 1125-1136.	1.9	8
14	Characterization of Antiphospholipid Syndrome Atherothrombotic Risk by Unsupervised Integrated Transcriptomic Analyses. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 865-877.	2.4	11
15	Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 631662.	4.8	13
16	Patients with Axial Spondyloarthritis Show an Altered Flexion/Relaxation Phenomenon. <i>Diagnostics</i> , 2021, 11, 810.	2.6	2
17	Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry. <i>Joint Bone Spine</i> , 2021, 88, 105136.	1.6	2
18	Prevalence and Associated Factors of Low Bone Mineral Density in the Femoral Neck and Total Hip in Axial Spondyloarthritis: Data from the CASTRO Cohort. <i>Journal of Clinical Medicine</i> , 2021, 10, 2664.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Potential Role and Impact of Peripheral Blood Mononuclear Cells in Radiographic Axial Spondyloarthritis-Associated Endothelial Dysfunction. <i>Diagnostics</i> , 2021, 11, 1037.	2.6	1
20	A Benchmarking Study Evaluating Axial Spondyloarthritis Burden in Spain and Other European Countries. Results from the Spanish Atlas and the European Map of Axial Spondyloarthritis (EMAS) Studies. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1127-1136.	1.9	2
21	Expression of DDX11 and DNM1L at the 12p11 Locus Modulates Systemic Lupus Erythematosus Susceptibility. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7624.	4.1	2
22	Remission in axial spondyloarthritis: Developing a consensus definition. <i>Reumatología Clínica</i> , 2021, 17, 380-387.	0.5	6
23	Future Challenges and Critical Approach to Metrology in Patients with Axial Spondyloarthritis. <i>Diagnostics</i> , 2021, 11, 1533.	2.6	1
24	Which factors explain the patient global assessment in patients with ankylosing spondylitis? A hierarchical cluster analysis on REGISPONSER-AS. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 875-879.	3.4	3
25	Remission in axial spondyloarthritis: Developing a consensus definition. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 380-387.	0.3	1
26	Assessment of Subclinical Psychotic Symptoms in Patients with Rheumatoid Arthritis and Spondyloarthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3461.	2.4	1
27	Mechanical Properties of Lumbar and Cervical Paravertebral Muscles in Patients with Axial Spondyloarthritis: A Case-Control Study. <i>Diagnostics</i> , 2021, 11, 1662.	2.6	9
28	Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2417-2430.	2.4	29
29	Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4070.	2.4	2
30	Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: data from the ASAS-COMOSPA study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X21110452.	2.7	7
31	Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 744022.	4.8	4
32	ASAS Health Index in patients with spondyloarthritis and its association with disease activity and disease burden including fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 82-88.	0.8	7
33	Consenso ASAS en nomenclatura en español para las espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 333-338.	0.5	4
34	Assessment of SpondyloArthritis International Society (ASAS) consensus on Spanish nomenclature for spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 333-338.	0.3	2
35	Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission. <i>Pediatric Rheumatology</i> , 2020, 18, 59.	2.1	14
36	Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. <i>Reumatología Clínica</i> , 2020, , .	0.5	1

#	ARTICLE	IF	CITATIONS
37	Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9067.	4.1	22
38	Hip and Shoulder Involvement and Their Management in Axial Spondyloarthritis: a Current Review. <i>Current Rheumatology Reports</i> , 2020, 22, 53.	4.7	7
39	Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Validation Study in Axial Spondyloarthritis. <i>Diagnostics</i> , 2020, 10, 426.	2.6	20
40	O31â€¦Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1
41	Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232096506.	2.5	12
42	Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. <i>Current Rheumatology Reports</i> , 2020, 22, 22.	4.7	4
43	Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1212.	4.1	20
44	Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies. <i>Haematologica</i> , 2020, 105, 2250-2261.	3.5	20
45	Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA. <i>Joint Bone Spine</i> , 2020, 87, 445-448.	1.6	14
46	Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF-Î± therapy effectiveness. <i>Journal of Biomedical Science</i> , 2020, 27, 54.	7.0	18
47	Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2098283.	2.7	13
48	Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. <i>Scientific Reports</i> , 2019, 9, 14812.	3.3	7
49	Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1988074.	2.7	7
50	Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 1111.	4.8	20
51	Atlas of axial spondyloarthritis in Spain 2017: Study design and population. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2019, 15, 127-132.	0.3	4
52	New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. <i>Frontiers in Immunology</i> , 2019, 10, 764.	4.8	30
53	Atlas of axial spondyloarthritis in Spain 2017: Study design and population. <i>ReumatologÃa ClÃnica</i> , 2019, 15, 127-132.	0.5	22
54	AB0698â€¦EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	AB0734Câ€...REMISSION IN AXIAL SPONDYLOARTHRITIS: A DELPHI-METHOD QUESTIONNAIRE AMONG EXPERTS TO EVALUATE THE AVAILABLE ASSESSMENT TOOLS TO MEASURE DISEASE ACTIVITY AND TO DEVELOP A CONSENSUS DEFINITION OF REMISSION. , 2019, , .		0
56	AB0725â€...ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION AND CARDIOVASCULAR RISK IN SPONDYLOARTHRITIS: DATA FROM COSPAR REGISTRY. , 2019, , .		0
57	Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 11.	3.5	42
58	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteenâ€Week Resultsâ€From a Phase <scp>III</scp> Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	5.6	142
59	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2019, 15, 77-83.	0.3	2
60	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 83-96.	2.0	10
61	Recomendaciones para la prescripciÃn de ejercicio fÃsico en pacientes con espondiloartritis. <i>ReumatologÃa ClÃnica</i> , 2019, 15, 77-83.	0.5	9
62	Facteurs de risque cardiovasculaire chez des patients atteints de spondyloarthrite originaires du nord de lâ€™Europe et des pays mÃ©diterranÃ©ensÃ: une Ã©tude dÃ©rivÃ©e du projet Asas-Comospa. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019, 86, 63-69.		0
63	Adherence to recommendations for the use of antiâ€tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. <i>Rheumatology</i> , 2018, 57, 880-890.	1.9	8
64	Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. <i>Clinical Rheumatology</i> , 2018, 37, 1581-1588.	2.2	38
65	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. <i>Human Molecular Genetics</i> , 2018, 27, 875-890.	2.9	58
66	Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. <i>Journal of Internal Medicine</i> , 2018, 284, 61-77.	6.0	34
67	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	3.5	30
68	Desarrollo de un cuadro de actuaciÃn para la evaluaciÃn de pacientes con espondiloartritis axial y artritis psoriÃsica en la prÃctica diaria: proyecto ONLY TOOLS. <i>ReumatologÃa ClÃnica</i> , 2018, 14, 155-159.	0.5	10
69	Recomendaciones para el manejo de la comorbilidad en la prÃctica clÃnica en pacientes con espondiloartritis axial. <i>ReumatologÃa ClÃnica</i> , 2018, 14, 346-359.	0.5	7
70	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. <i>Joint Bone Spine</i> , 2018, 85, 447-453.	1.6	21
71	AB0867â€...Axial spondyloarthritis posture assessment using inertial sensors. , 2018, , .		1
72	AB0353â€...Genetically predisposition and pro-inflammatory dysregulations â€ connecting rheumatoid arthritis and mental disorders. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
73	SAT0331â€¦Inflammatory markers and adipokines related to cardiovascular risk and metabolic comorbidities in psoriatic arthritis. in vivo effects of apremilast. , 2018, , .		0
74	Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database. Arthritis Research and Therapy, 2018, 20, 221.	3.5	62
75	Neutrophils: Novel key players in Rheumatoid Arthritis. Current and future therapeutic targets. Autoimmunity Reviews, 2018, 17, 1138-1149.	5.8	88
76	Development of a Checklist for Patients With Axial Spondyloarthritis and Psoriatic Arthritis in Daily Practice: ONLY TOOLS Project. ReumatologÃa ClÃnica (English Edition), 2018, 14, 155-159.	0.3	2
77	High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1383-1388.	2.0	6
78	FRI0215â€¦Asas consensus on spanish nomenclature for spondyloarthritis. , 2018, , .		0
79	THU0297â€¦Evaluation of cardiovascular risk factors among patients with psoriasis, psoriatic arthritis and peripheral spondyloarthritis. , 2018, , .		0
80	THU0076â€¦Antibodies to citrullinated protein antigens (ACPAS) induce adipose tissue dysfunction impairing adipocyte differentiation, lipid accumulation and promoting macrophage polarisation. in vitro effect of biologic dmards. , 2018, , .		0
81	AB0394â€¦Observational study of the incidence of cardiovascular events and associated comorbidities in a cohort of patients with recent onset rheumatoid arthritis. , 2018, , .		0
82	THU0576â€¦Cardiovascular risk in long-term juvenile idiopathic arthritis. , 2018, , .		0
83	Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. Arthritis Care and Research, 2017, 69, 150-155.	3.4	22
84	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. Rheumatology International, 2017, 37, 1239-1248.	3.0	24
85	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. Journal of Autoimmunity, 2017, 82, 31-40.	6.5	82
86	Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. Rheumatology International, 2017, 37, 1701-1708.	3.0	2
87	Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Translational Research, 2017, 183, 87-103.	5.0	80
88	FRI0429â€¦Dysregulation of the splicing machinery in leukocytes from ankylosing spondylitis patients is associated to disease pathogenesis. , 2017, , .		0
89	OP0238â€¦Measurement of spinal mobility in axial spondyloarthritis using inertial sensors: reliability and validation preliminary results. , 2017, , .		0
90	Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). Rheumatology International, 2017, 37, 1817-1823.	3.0	19

#	ARTICLE	IF	CITATIONS
91	AB0127â€¦ANTI-DS-DNA antibodies regulate atherothrombosis in systemic lupus erythematosus through the induction of netosis, inflammation and endothelial activation. , 2017, , .		0
92	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1923-1932.	2.4	60
93	THU0218â€¦Circulating micrnas as biomarkers for diagnosis and typifying the atherothrombotic status in antiphospholipid syndrome. , 2017, , .		0
94	PARE0020â€¦25 years of patients' associations of ankylosing spondylitis in spain: aceade. , 2017, , .		0
95	FRIO048â€¦The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells. , 2017, , .		0
96	FRIO452â€¦Impact of a training program and early referral on diagnostic delay in patients with axial spondyloarthritis: results from the spanish atlas. , 2017, , .		0
97	THU0380â€¦Results of a real life dose-reduction strategy for anti-tnfalpa inhibitors in a cohort of patients with spondyloarthritis. , 2017, , .		0
98	FRIO360â€¦Analysis of endocannabinoid system elements and related inflammatory molecules in peripheral blood leukocytes of patients with systemic sclerosis. , 2017, , .		0
99	AB0619â€¦Connective tissue disease-associated interstitial lung disease treated with cyclophosphamide or rituximab: a unicentre, open-label and comparative study. , 2017, , .		0
100	FRIO434â€¦Poor quality of life in patients with spondyloarthritis is not explained by structural damage. data from regisponser. , 2017, , .		0
101	THU0624â€¦Asessment of psychic experiences in patients with rheumatic diseases. , 2017, , .		1
102	SAT0412â€¦Association between smoking with spinal level of stiffness and functional limitation in patients with axial spondyloarthritis: results from the spanish atlas. , 2017, , .		0
103	SAT0391â€¦Lumbar flexion/relaxation phenomenon in patients with axial spondyloarthritis. , 2017, , .		0
104	SAT0447â€¦Prevalence of radiographic sacroiliitis in patients with psoriatic arthritis and the clinical, analytical and demographic factors associated to its appearance. , 2017, , .		0
105	FRIO431â€¦Altered expression of circulating micrnas is related to disease activity and structural damage in ankylosing spondylitis patients. , 2017, , .		0
106	AB0694â€¦Inertial Sensor for The Assessment of Cervical Range of Movement in Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 1141.4-1142.	0.9	1
107	â€ˆAtherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. Scientific Reports, 2016, 6, 31375.	3.3	44
108	THU0243â€¦Integrated Analysis of Micrna and MRNA Expression Profiles Related To Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus Patients. Annals of the Rheumatic Diseases, 2016, 75, 276.1-276.	0.9	0

#	ARTICLE	IF	CITATIONS
109	THU0254â€¦In Vivo Ubiquinol (COQ10) Supplementation Reduces The Atherothrombotic Status of Antiphospholipid Syndrome Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 280.1-280.	0.9	0
110	OPO310â€¦Association of Neutrophil Extracellular Traps with Atherosclerosis in Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 175.1-175.	0.9	0
111	AB0104â€¦Role of CD14+ and CD16+ Monocyte Subtypes in The Atherothrombosis Associated with Rheumatoid Arthritis: Epigenetic Mechanisms Involved. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 932.1-932.	0.9	0
112	FRI0046â€¦TCZ Attenuates Atherothrombosis through The Specific Inhibition of Netosis and Monocyte-Mediated Proinflammatory Activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 442.3-443.	0.9	0
113	FRI0056â€¦Altered Microrna Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals The Pathogenic Profile of These Cells. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 446.1-446.	0.9	0
114	AB0116â€¦Induction of Netosis-Mediated Cell Death in Ankylosing Spondylitis Patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 936.2-936.	0.9	0
115	AB0124â€¦Peripheral Blood Mononuclear Cells from Ankylosing Spondylitis Patients Display An Atherogenic Profile Associated with Disease Activity and Endothelial Dysfunction. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 939.1-939.	0.9	0
116	THU0255â€¦Identification of Novel Regulatory Networks Related To Atherothrombosis in Monocytes from Antiphospholipid Syndrome through Integrated Analysis of Microrna/mrna/protein Expression Profiles. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 280.2-280.	0.9	0
117	Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. <i>Rheumatology</i> , 2016, 55, 2096-2108.	1.9	59
118	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	3.0	5
119	THU0400â€¦Relationship between Health Quality of Life and Other Indicators in Patients with Axial Spondyloarthritis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 333.1-333.	0.9	0
120	FRI0394â€¦Assessment of Cardiovascular Risk Factors in Patients with Spondyloarthritis and Their Association with Disease Features and Its Activity. A Comparison between Two Population Groups from Asas-Comospa. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 577.2-578.	0.9	0
121	Inter-rater reliability of clinical mobility measures in ankylosing spondylitis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 382.	1.9	16
122	Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. <i>Medicine (United States)</i> , 2016, 95, e5652.	1.0	72
123	Upswings in Cheerful Mood and Disease Activity in Patients with Rheumatoid Arthritis. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 606-610.	1.7	13
124	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.9	53
125	Assessment of Fatigue in Spondyloarthritis and Its Association with Disease Activity. <i>Journal of Rheumatology</i> , 2016, 43, 751-757.	2.0	20
126	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	3.0	10



#	ARTICLE	IF	CITATIONS
127	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
128	AB0133â€...Role of Monocytes Subsets in the Atherothrombosis and Endothelial Dysfunction Associated with Rheumatoid Arthritis: Beneficial Effects of Tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 935.2-935.	0.9	0
129	Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 432-443.	1.5	14
130	THU0398â€...Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 340.3-341.	0.9	2
131	FRIO190â€...Role of Leukocyte Subsets in the Inflammation, Oxidative Stress and Bone Turnover in Ankylosing Spondylitis Patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 493.2-493.	0.9	0
132	FRIO218â€...Structural Damage Distribution at Vertebral Level in Patients with Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 503.2-504.	0.9	0
133	AB0165â€...Regulation of Atherothrombosis in Systemic Lupus Erythematosus. Role of Different Monocyte Subsets, Netosis Involvement, and Effects of Anti-Dsdna Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 945.3-946.	0.9	0
134	AB0134â€...Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of Anti-CCPS in the Phenotypic Switching and the Insulin Signalling. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 935.3-936.	0.9	0
135	Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 323-333.	1.5	17
136	Is Spinal Mobility in Patients With Spondylitis Determined By Age, Structural Damage, and Inflammation?. <i>Arthritis Care and Research</i> , 2015, 67, 74-79.	3.4	29
137	Recomendaciones para la detecciÃ³n, investigaciÃ³n y derivaciÃ³n del dolor lumbar inflamatorio en AtenciÃ³n Primaria. <i>ReumatologÃ­a ClÃ­nica</i> , 2015, 11, 90-98.	0.5	13
138	Reccomendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. <i>ReumatologÃ­a ClÃ­nica (English Edition)</i> , 2015, 11, 90-98.	0.3	5
139	Nonradiographic axial spondyloarthritis. What brings the new concept?. <i>Clinical Rheumatology</i> , 2015, 34, 195-197.	2.2	1
140	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFÎ±. <i>Arthritis Research and Therapy</i> , 2015, 17, 49.	3.5	158
141	Polymorphisms of HLAâ€A, â€B, â€Cw and DRB1 antigens in Moroccan patients with ankylosing spondylitis and a comparison of clinical features with frequencies of <i>HLAâ€B*27</i>. <i>Tissue Antigens</i> , 2015, 85, 108-116.	1.0	10
142	OP0156â€...In Vitro Treatment with Anti-Cardiolipin and Anti-DSDNA Antibodies Modifies the Expression of Micrnas Related to Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 128.1-128.	0.9	0
143	Positive and negative affective states and disease activity in ankylosing spondylitis. <i>Rheumatology International</i> , 2015, 35, 519-524.	3.0	11
144	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1441-1449.	0.9	76

#	ARTICLE	IF	CITATIONS
145	Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1450-1458.	0.9	49
146	AB0733â€œ...Which Chronic Back Pain (CBP) Characteristics Are Associated with A Positive HLA-B27 in Patients with Suspected Axial Spondyloarthritis (AXSPA)? Results from the Esperanza Cohort: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1045.2-1046.	0.9	0
147	Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2706-2716.	2.4	52
148	AB0188â€œ...Atherosclerosis and Cardiovascular Disease in Systemic Lupus Erythematosus. Effects of Statins Treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 865.2-865.	0.9	0
149	SAT0420â€œ...Ground Reaction Forces in Patients with Knee Osteoarthritis after Intra-Articular Treatments:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 746.3-747.	0.9	0
150	Candidateâ€œ™s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis. <i>Rheumatology International</i> , 2014, 34, 793-801.	3.0	12
151	Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). <i>Rheumatology International</i> , 2014, 34, 401-406.	3.0	18
152	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. <i>Rheumatology</i> , 2014, 53, 353-360.	1.9	35
153	Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors. <i>Journal of Rheumatology</i> , 2014, 41, 2409-2412.	2.0	5
154	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2014, 10, 204-209.	0.3	1
155	Development and Validation of a New Instrument to Measure Health-related Quality of Life in Patients with Psoriatic Arthritis: The VITACORA-19. <i>Journal of Rheumatology</i> , 2014, 41, 2008-2017.	2.0	14
156	Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1350-1355.	0.9	46
157	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
158	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>ReumatologÃa ClÃnica</i> , 2014, 10, 204-209.	0.5	24
159	OP0188â€œ...Circulating Mirnas as Potential Biomarkers of Therapy Effectiveness in Rheumatoid Arthritis Patients Treated with Anti-TNF. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 133.3-134.	0.9	1
160	AB0164â€œ...Analysis of Jak-Stat-Socs Signal Pathway MRNA Expression in Ankylosing Spondylitis (AS) Patients with Peripheral Arthritis (PA). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 857.1-857.	0.9	0
161	FRIO129â€œ...Similarities and Differences between Axial and Peripheral Predominant Forms in Patients with Early Spondyloarthritis: Results from the Esperanza Cohort:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 428.2-429.	0.9	0
162	Nuevos paradigmas en el diagnÃ³stico y la clasificaciÃ³n de las espondiloartritis. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 199-200.	0.5	6

#	ARTICLE	IF	CITATIONS
163	Comparación de 2 estrategias de derivación en el diagnóstico de la espondiloartritis axial en España. Estudio RADAR. <i>Reumatología Clínica</i> , 2013, 9, 348-352.	0.5	6
164	Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER. <i>Reumatología Clínica</i> , 2013, 9, 221-225.	0.5	23
165	Modelo de excelencia en el Hospital de Dña de Reumatología en España: proyecto HD-Reumatolex. <i>Reumatología Clínica</i> , 2013, 9, 142-147.	0.5	9
166	New Paradigms in the Diagnosis and Classification of the Spondylarthritis. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 199-200.	0.3	1
167	Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONSER. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 221-225.	0.3	7
168	Recent updates on the recommendations for the management of ankylosing spondylitis: what and why?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 361-371.	0.3	1
169	Hip disease in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 448-454.	4.3	69
170	SAT0044...Anti-cyclic citrullinated protein antibodies induce inflammation and oxidative stress in monocytes and neutrophils of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 485.3-485.	0.9	0
171	SAT0161...Fluvastatin treatment prevents the inflammatory/oxidative status linked to the clinical activity of the disease in systemic lupus erythematosus patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 526.2-526.	0.9	0
172	THU0411...Utility of ultrasound scores in assessment enthesitis on anti-TNF therapy of spondyloarthritis patients:. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 294.1-294.	0.9	0
173	Gender-Specific Effects of Genetic Variants within Th1 and Th17 Cell-Mediated Immune Response Genes on the Risk of Developing Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e72732.	2.5	20
174	An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 484-9.	0.8	20
175	A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 714-717.	0.9	14
176	Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. <i>Rheumatology</i> , 2012, 51, 1471-1478.	1.9	18
177	Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. <i>Blood</i> , 2012, 119, 5859-5870.	1.4	82
178	Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America. <i>Journal of Rheumatology</i> , 2012, 39, 2315-2320.	2.0	44
179	Assessment of spinal mobility in ankylosing spondylitis using a video-based motion capture system. <i>Manual Therapy</i> , 2012, 17, 422-426.	1.6	30
180	Clinical Features of Late-onset Ankylosing Spondylitis: Comparison with Early-onset Disease. <i>Journal of Rheumatology</i> , 2012, 39, 1008-1012.	2.0	40

#	ARTICLE	IF	CITATIONS
181	Both Baseline Clinical Factors and Genetic Polymorphisms Influence the Development of Severe Functional Status in Ankylosing Spondylitis. <i>PLoS ONE</i> , 2012, 7, e43428.	2.5	9
182	Prevalence of Vertebral Fractures by Semiautomated Morphometry in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 893-897.	2.0	57
183	A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1957-1962.	0.9	159
184	Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in Spondyloarthritis except for Psoriatic Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 113-123.	0.3	10
185	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
186	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 896-904.	0.9	831
187	311 INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO MITOCHONDRIAL DEPolarISATION AND OXIDATIVE STRESS. <i>Atherosclerosis Supplements</i> , 2011, 12, 67.	1.2	0
188	414 OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME. <i>Atherosclerosis Supplements</i> , 2011, 12, 89.	1.2	0
189	Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2011, 30, 691-695.	2.2	31
190	Fine mapping of a major histocompatibility complex in ankylosing spondylitis: Association of the <i>HLA*DPA1</i> and <i>HLA*DPB1</i> regions. <i>Arthritis and Rheumatism</i> , 2011, 63, 3305-3312.	6.7	17
191	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 973-981.	0.9	158
192	A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 827-830.	0.9	37
193	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 675-682.	0.9	82
194	Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2011, 38, 1656-1660.	2.0	77
195	High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011, 50, 1828-1837.	1.9	38
196	Usefulness of a centralized system of data collection for the development of an international multicentre registry of spondyloarthritis. <i>Rheumatology</i> , 2011, 50, 132-136.	1.9	10
197	Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 869-877.	6.7	52
198	Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1000-1006.	6.7	51

#	ARTICLE	IF	CITATIONS
199	Current Controversies in Spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010, 37, 2617-2623.	2.0	11
200	Association of the Intergenic Single-Nucleotide Polymorphism rs10865331 (2p15) with Ankylosing Spondylitis in a Spanish Population. <i>Journal of Rheumatology</i> , 2010, 37, 2345-2347.	2.0	7
201	Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases. <i>Pharmacology</i> , 2009, 83, 211-216.	2.2	18
202	First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early). <i>Rheumatology</i> , 2009, 48, 404-409.	1.9	77
203	Fast detection of marker pixels in video-based motion capture systems. <i>Pattern Recognition Letters</i> , 2009, 30, 432-439.	4.2	3
204	New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 784-788.	0.9	498
205	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 770-776.	0.9	731
206	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 777-783.	0.9	2,713
207	Work Disability in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 2512-2516.	2.0	48
208	First Acute Gout Attacks Commonly Precede Features of the Metabolic Syndrome. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 65-67.	0.9	21
209	The Burden of Ankylosing Spondylitis in Spain. <i>Value in Health</i> , 2008, 11, 408-415.	0.3	37
210	Fat overload aggravates oxidative stress in patients with the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008, 38, 510-515.	3.4	50
211	Anakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. <i>Joint Bone Spine</i> , 2008, 75, 504-505.	1.6	114
212	Chondrocalcinosis and Hypomagnesemia: Clinical and Radiological Progression. <i>Reumatología Clínica (English Edition)</i> , 2008, 4, 37-39.	0.3	2
213	Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. <i>Rheumatology</i> , 2008, 47, 355-361.	1.9	96
214	The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 62-71.	1.1	18
215	Ankylosing spondylitis and other spondyloarthropathies: extra-articular manifestations and their management. <i>Future Rheumatology</i> , 2008, 3, 457-473.	0.2	0
216	Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 782-788.	0.9	31

#	ARTICLE	IF	CITATIONS
217	Decreased levels of uric acid after oral glucose challenge is associated with triacylglycerol levels and degree of insulin resistance. <i>British Journal of Nutrition</i> , 2008, 99, 44-48.	2.3	12
218	Circulating antioxidant defences are decreased in healthy people after a high-fat meal. <i>British Journal of Nutrition</i> , 2008, 100, 312-316.	2.3	24
219	The effect of infliximab on oxidative stress in chronic inflammatory joint disease. <i>Current Medical Research and Opinion</i> , 2007, 23, 1259-1267.	1.9	30
220	Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. <i>Rheumatology</i> , 2007, 46, 1309-1315.	1.9	160
221	Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1218-1221.	0.9	50
222	Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. <i>Future Rheumatology</i> , 2007, 2, 545-565.	0.2	7
223	Digital Densitometry for Evaluation of Osteoporosis in Spondyloarthropathy Patients. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 111-112.	0.9	0
224	L'association au méthotrexate améliore l'efficacité de l'infliximab dans la spondylarthrite ankylosante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 470-474.	0.0	0
225	Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2007, 74, 254-258.	1.6	31
226	ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 442-452.	0.9	571
227	An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1620-1625.	0.9	43
228	Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 85-88.	0.9	46
229	Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. <i>Rheumatology</i> , 2005, 44, 1555-1558.	1.9	23
230	Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2005, 44, 1132-1135.	1.9	55
231	Assessment of the efficacy of joint lavage versus joint lavage plus corticoids in patients with osteoarthritis of the knee. <i>Current Medical Research and Opinion</i> , 2004, 20, 861-867.	1.9	25
232	Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. <i>Current Medical Research and Opinion</i> , 2004, 20, 155-157.	1.9	114
233	Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1239-1240.	0.9	32
234	Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. <i>Current Medical Research and Opinion</i> , 2003, 19, 402-410.	1.9	51

#	ARTICLE	IF	CITATIONS
235	ICAM-1 Expression on the Surface of T Lymphocytes in Patients with Uveitis: A Comparative Study between the Eye and Peripheral Blood. <i>Ophthalmologica</i> , 2002, 216, 203-208.	1.9	6
236	Distribution of HLA-DRB1 genes in patients with sporadic ankylosing spondylitis in the south of Spain. <i>Joint Bone Spine</i> , 2002, 69, 458-462.	1.6	8
237	Distribution du gène HLA-DRB1 dans une population de patients atteints de spondylarthrite ankylosante sporadique du sud de l'Espagne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002, 69, 886-891.	0.0	0
238	Design and performance of a multi-centre randomised controlled trial and economic evaluation of joint tele-consultations [ISRCTN54264250]. <i>BMC Family Practice</i> , 2002, 3, 1.	2.9	42
239	The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice. <i>Journal of Rheumatology</i> , 2002, 29, 326-30.	2.0	19
240	Aqueous Humor and Serum Tumor Necrosis Factor- $\alpha$ in Clinical Uveitis. <i>Ophthalmic Research</i> , 2001, 33, 251-255.	1.9	287
241	Can some cases of "possible" spondyloarthropathy be classified as "definite" or "undifferentiated" spondyloarthropathy? Value of criteria for spondyloarthropathies. <i>Joint Bone Spine</i> , 2000, 67, 516-520.	1.6	63
242	Osteonecrosis of the tibial plateau. <i>Clinical Rheumatology</i> , 1998, 17, 95-98.	2.2	6
243	Dietary Alterations in Plasma Very Low Density Lipoprotein Levels Modify Renal Excretion of Urates in Hyperuricemic-Hypertriglyceridemic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1188-1191.	3.6	31
244	Quantification of Joint Laxity. "The Non-Dominant (Spanish) Modification". <i>Rheumatology</i> , 1995, 34, 795-796.	1.9	4
245	Assessment of 2 systems of spondyloarthropathy diagnostic and classification criteria (Amor and Tj ETQq1 1 0.784314 rgBT /Overlook). <i>Rheumatology</i> , 1995, 22, 246-51.	2.0	52